Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Niagen Bioscience Inc (NASDAQ: NAGE) was $9.82 for the day%, Up $0.92% from the previous closing price of $9.73. In other words, the price has increased by $0.92 from its previous closing price. On the day, 1.43 million shares were traded. NAGE stock price reached its highest trading level at $10.3 during the session, while it also had its lowest trading level at $9.74.
Ratios:
Our analysis of NAGE’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.95 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 37.51. For the most recent quarter (mrq), Quick Ratio is recorded 3.24 and its Current Ratio is at 3.88. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Canaccord Genuity on May 27, 2025, initiated with a Buy rating and assigned the stock a target price of $13.
B. Riley Securities Downgraded its Buy to Neutral on August 11, 2022, whereas the target price for the stock was revised from $6 to $2.40.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 07 ’25 when Lopez Carlos Luis bought 273 shares for $7.86 per share. The transaction valued at 2,146 led to the insider holds 2,251 shares of the business.
Jaksch Frank L Jr sold 37,161 shares of NAGE for $229,956 on Dec 13 ’24. The Director now owns 244,179 shares after completing the transaction at $6.19 per share. On Dec 13 ’24, another insider, Frank Jaksch Jr., who serves as the affiliate of the company, bought 37,161 shares for $6.19 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAGE now has a Market Capitalization of 783174464 and an Enterprise Value of 727784000. As of this moment, Niagen’s Price-to-Earnings (P/E) ratio for their current fiscal year is 45.74, and their Forward P/E ratio for the next fiscal year is 36.04. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.85. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.73 while its Price-to-Book (P/B) ratio in mrq is 12.17. Its current Enterprise Value per Revenue stands at 6.258 whereas that against EBITDA is 41.702.
Stock Price History:
The Beta on a monthly basis for NAGE is 2.22, which has changed by 2.2302632 over the last 52 weeks, in comparison to a change of 0.17279088 over the same period for the S&P500. Over the past 52 weeks, NAGE has reached a high of $14.69, while it has fallen to a 52-week low of $2.69. The 50-Day Moving Average of the stock is -15.70%, while the 200-Day Moving Average is calculated to be 23.33%.
Shares Statistics:
NAGE traded an average of 1.13M shares per day over the past three months and 1468660 shares per day over the past ten days. A total of 79.59M shares are outstanding, with a floating share count of 51.42M. Insiders hold about 35.52% of the company’s shares, while institutions hold 32.48% stake in the company. Shares short for NAGE as of 1752537600 were 3492241 with a Short Ratio of 3.09, compared to 1749772800 on 3272948. Therefore, it implies a Short% of Shares Outstanding of 3492241 and a Short% of Float of 6.75.
Earnings Estimates
The dynamic stock of Niagen Bioscience Inc (NAGE) is currently attracting attention from 2.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is $0.02, with high estimates of $0.02 and low estimates of $0.02.
Analysts are recommending an EPS of between $0.15 and $0.13 for the fiscal current year, implying an average EPS of $0.14. EPS for the following year is $0.22, with 2.0 analysts recommending between $0.22 and $0.21.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $31.5M to a low estimate of $29.6M. As of the current estimate, Niagen Bioscience Inc’s year-ago sales were $25.58MFor the next quarter, 5 analysts are estimating revenue of $33.7M. There is a high estimate of $34.4M for the next quarter, whereas the lowest estimate is $32.5M.
A total of 5 analysts have provided revenue estimates for NAGE’s current fiscal year. The highest revenue estimate was $126.66M, while the lowest revenue estimate was $125.5M, resulting in an average revenue estimate of $126.01M. In the same quarter a year ago, actual revenue was $99.6MBased on 4 analysts’ estimates, the company’s revenue will be $152.59M in the next fiscal year. The high estimate is $158M and the low estimate is $148.56M.
